L
Lineage Cell Therapeutics Inc
F:BT3
Lineage Cell Therapeutics Inc
F:BT3
Price:
1.078
EUR
-1.82%
Market Cap:
€203.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
I
|
Instalco AB
F:4II
|
SE |
|
R
|
Rush Enterprises Inc
F:RUNA
|
US |
|
I
|
Iovance Biotherapeutics Inc
F:2LB
|
US |
|
R
|
Resona Holdings Inc
XMUN:DW1
|
JP |
|
T
|
Takeda Pharmaceutical Co Ltd
XHAM:TKD
|
JP |
|
B
|
Booking Holdings Inc
XMUN:PCE1
|
US |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Wall Street analysts forecast BT3 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for BT3 is 5.779 EUR with a low forecast of 3.121 EUR and a high forecast of 9.734 EUR.
Lowest Forecast
Price Target
3.121
EUR
190% Upside
Average Forecast
Price Target
5.779
EUR
436% Upside
Highest Forecast
Price Target
9.734
EUR
803% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
5.779
EUR
5.779
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 5.779 EUR with a low forecast of 3.121 EUR and a high forecast of 9.734 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
58%
58%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 58%.
